Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) Assets Average (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Assets Average for 15 consecutive years, with $4.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Assets Average rose 2.81% year-over-year to $4.2 million, compared with a TTM value of $4.2 million through Sep 2025, up 2.81%, and an annual FY2024 reading of $5.5 million, down 84.95% over the prior year.
  • Assets Average was $4.2 million for Q3 2025 at Alaunos Therapeutics, up from $3.4 million in the prior quarter.
  • Across five years, Assets Average topped out at $137.4 million in Q1 2021 and bottomed at $2.4 million in Q1 2025.
  • Average Assets Average over 5 years is $49.4 million, with a median of $38.3 million recorded in 2023.
  • The sharpest move saw Assets Average tumbled 87.41% in 2024, then increased 2.81% in 2025.
  • Year by year, Assets Average stood at $104.3 million in 2021, then plummeted by 36.59% to $66.1 million in 2022, then plummeted by 79.06% to $13.9 million in 2023, then tumbled by 77.24% to $3.2 million in 2024, then soared by 34.16% to $4.2 million in 2025.
  • Business Quant data shows Assets Average for TCRT at $4.2 million in Q3 2025, $3.4 million in Q2 2025, and $2.4 million in Q1 2025.